These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 28485312)

  • 1. Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study.
    Zhao HY; Gu J; Lyu J; Liu D; Wang YT; Liu F; Zhu FX; An YZ
    Chin Med J (Engl); 2017 May; 130(10):1139-1145. PubMed ID: 28485312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
    Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial.
    Chytra I; Stepan M; Benes J; Pelnar P; Zidkova A; Bergerova T; Pradl R; Kasal E
    Crit Care; 2012 Jun; 16(3):R113. PubMed ID: 22742765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units.
    Jaruratanasirikul S; Thengyai S; Wongpoowarak W; Wattanavijitkul T; Tangkitwanitjaroen K; Sukarnjanaset W; Jullangkoon M; Samaeng M
    Antimicrob Agents Chemother; 2015; 59(6):2995-3001. PubMed ID: 25753628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
    Jamal JA; Mat-Nor MB; Mohamad-Nor FS; Udy AA; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2015 Jan; 45(1):41-5. PubMed ID: 25455853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous infusion versus intermittent administration of meropenem in critically ill patients.
    Thalhammer F; Traunmüller F; El Menyawi I; Frass M; Hollenstein UM; Locker GJ; Stoiser B; Staudinger T; Thalhammer-Scherrer R; Burgmann H
    J Antimicrob Chemother; 1999 Apr; 43(4):523-7. PubMed ID: 10350382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
    Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Meropenem Extended Versus Intermittent Infusion Dosing Protocol in Critically Ill Patients.
    Ahmed N; Jen SP; Altshuler D; Papadopoulos J; Pham VP; Dubrovskaya Y
    J Intensive Care Med; 2020 Aug; 35(8):763-771. PubMed ID: 29954243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial.
    Dulhunty JM; Roberts JA; Davis JS; Webb SA; Bellomo R; Gomersall C; Shirwadkar C; Eastwood GM; Myburgh J; Paterson DL; Lipman J
    Clin Infect Dis; 2013 Jan; 56(2):236-44. PubMed ID: 23074313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis.
    Pařízková RČ; Martínková J; Havel E; Šafránek P; Kaška M; Astapenko D; Bezouška J; Chládek J; Černý V
    Crit Care; 2021 Jul; 25(1):251. PubMed ID: 34274013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial.
    Brunkhorst FM; Oppert M; Marx G; Bloos F; Ludewig K; Putensen C; Nierhaus A; Jaschinski U; Meier-Hellmann A; Weyland A; Gründling M; Moerer O; Riessen R; Seibel A; Ragaller M; Büchler MW; John S; Bach F; Spies C; Reill L; Fritz H; Kiehntopf M; Kuhnt E; Bogatsch H; Engel C; Loeffler M; Kollef MH; Reinhart K; Welte T;
    JAMA; 2012 Jun; 307(22):2390-9. PubMed ID: 22692171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial.
    Monti G; Bradic N; Marzaroli M; Konkayev A; Fominskiy E; Kotani Y; Likhvantsev VV; Momesso E; Nogtev P; Lobreglio R; Redkin I; Toffoletto F; Bruni A; Baiardo Redaelli M; D'Andrea N; Paternoster G; Scandroglio AM; Gallicchio F; Ballestra M; Calabrò MG; Cotoia A; Perone R; Cuffaro R; Montrucchio G; Pota V; Ananiadou S; Lembo R; Musu M; Rauch S; Galbiati C; Pinelli F; Pasin L; Guarracino F; Santarpino G; Agrò FE; Bove T; Corradi F; Forfori F; Longhini F; Cecconi M; Landoni G; Bellomo R; Zangrillo A;
    JAMA; 2023 Jul; 330(2):141-151. PubMed ID: 37326473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli.
    Lorente L; Lorenzo L; Martín MM; Jiménez A; Mora ML
    Ann Pharmacother; 2006 Feb; 40(2):219-23. PubMed ID: 16449546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy.
    Langgartner J; Vasold A; Glück T; Reng M; Kees F
    Intensive Care Med; 2008 Jun; 34(6):1091-6. PubMed ID: 18297267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
    Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A
    Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of meropenem in critically ill patients with severe infections.
    Binder L; Schwörer H; Hoppe S; Streit F; Neumann S; Beckmann A; Wachter R; Oellerich M; Walson PD
    Ther Drug Monit; 2013 Feb; 35(1):63-70. PubMed ID: 23318279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.
    Arnold HM; Hollands JM; Skrupky LP; Smith JR; Juang PH; Hampton NB; McCormick S; Reichley RM; Hoban A; Hoffmann J; Micek ST; Kollef MH
    Ann Pharmacother; 2013 Feb; 47(2):170-80. PubMed ID: 23341160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
    Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
    Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two empirical prolonged infusion dosing regimens for meropenem in patients with septic shock: A two-center pilot study.
    Eisert A; Lanckohr C; Frey J; Frey O; Wicha SG; Horn D; Ellger B; Schuerholz T; Marx G; Simon TP
    Int J Antimicrob Agents; 2021 Mar; 57(3):106289. PubMed ID: 33515688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adequate antibiotic therapy prior to ICU admission in patients with severe sepsis and septic shock reduces hospital mortality.
    Garnacho-Montero J; Gutiérrez-Pizarraya A; Escoresca-Ortega A; Fernández-Delgado E; López-Sánchez JM
    Crit Care; 2015 Aug; 19(1):302. PubMed ID: 26307060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.